Skip to main content

Table 1 Demographic and clinical characteristics for cervical cancer patients diagnosed with and without liver metastasis

From: Incidence, clinical risk and prognostic factors for liver metastasis in patients with cervical cancer: a population-based retrospective study

Subject characteristics No. of cervical cancer patients (2010–2015) χ2 P-value
With LM
(N = 431, 2.32%)
Without LM
(N = 18,127, 97.68%)
Age in years    68.154 < 0.001
 18–40 55 (12.8%) 5320 (28%)   
 41–64 244 (56.6%) 10,125 (53.3%)   
  ≥ 65 132 (30.6%) 3544 (18.7%)   
Year of diagnosis    3.63 0.163
 2010–2011 124 (28.8%) 6292 (33.1%)   
 2012–2013 149 (32.6%) 6175 (32.5%)   
 2014–2015 158 (36.7%) 6522 (34.35)   
Race    17.867 0.001
 White 296 (68.7%) 14,170 (74.6%)   
 Black 88 (20.4%) 2620 (13.8%)   
 Others 46 (10.7%) 2005 (10.6%)   
 Unknown 1 (0.2%) 194 (1.0%)   
Marital status    1.183 0.553
 Married 263 (61.0%) 12,062 (63.5%)   
 Unmarried 138 (32.0%) 5733 (30.2%)   
 Unknown 30 (7.0%) 1194 (6.3%)   
Insurance    6.827 0.033
 Insured 380 (88.2%) 17,242 (90.8%)   
 Uninsured 41 (9.5%) 1220 (6.4%)   
 Unknown 10 (2.3%) 527 (2.8%)   
Primary Site    20.689 < 0.001
 Endocervix 48 (11.1%) 3590 (18.9%)   
 Exocervix 3 (0.7%) 341 (1.8%)   
 Overlapping lesion of cervix 7 (1.6%) 304 (1.6%)   
 Cervix uteri, unspecified 373 (86.5%) 14,754 (77.7%)   
AJCC stage
 T stage    169.341 < 0.001
  T1 59 (13.7%) 10,397 (54.8%)   
  T2 73 (16.9%) 4170 (22.0%)   
  T3 144 (33.4%) 2911 (15.3%)   
  T4 61 (14.2%) 671 (3.5%)   
  Unknown 94 (21.8%) 840 (4.4%)   
 N stage    468.148 < 0.001
  N0 124 (28.8%) 13,554 (71.4%)   
  N1 218 (50.6%) 4622 (24.3%)   
  Unknown 89 (20.6%) 813 (4.3%)   
Grade    615.394 < 0.001
 I 4 (0.9%) 2141 (11.3%)   
 II 54 (12.5%) 5940 (31.3%)   
 III 175 (40.6%) 5353 (28.2%)   
 IV 28 (6.5%) 417 (2.2%)   
 Unknown 170 (39.4%) 5138 (27.1%)   
Histology    132.849 < 0.001
 SCC 207 (48.0%) 12,429 (65.5%)   
 AC 97 (22.5%) 4366 (23.05)   
 Others 127 (29.5%) 2194 (11.6%)   
Tumor size    152.343 < 0.001
  ≤ 2 cm 12 (2.8%) 4168 (21.9%)   
  > 2, ≤4 cm 31 (7.2%) 3031 (16.0%)   
  > 4 cm 140 (39.4%) 5861 (30.9%)   
 Unknown 218 (50.6%) 5929 (31.2%)   
Surgery primary site    365.563 < 0.001
 Yes 386 (89.6%) 8243 (43.4%)   
 No 45 (10.4%) 10,712 (56.4%)   
 Unknown 0 (0.0%) 34 (0.2%)   
Lung Met    2397.509 < 0.001
 No 204 (47.3%) 18,331 (96.5%)   
 Yes 204 (47.3%) 622 (3.3%)   
 Unknown 23 (5.3%) 36 (0.2%)   
Bone Met    1723.957 < 0.001
 No 286 (66.4%) 18,634 (98.1%)   
 Yes 128 (29.7%) 330 (1.7%)   
 Unknown 17 (3.9%) 25 (0.1%)   
Brain Met    685.061 < 0.001
 No 391 (90.7%) 18,911 (99.6%)   
 Yes 18 (4.2%) 61 (0.3%)   
 Unknown 22 (5.1%) 17 (0.1%)   
Radiotherapy    8.924 0.003
 Yes 206 (47.8%) 10,451 (55.0%)   
 No/ Unknown 225 (52.2%) 8538 (45.0%)   
Chemotherapy    22.572 < 0.001
 Yes 263 (61.0%) 9390 (49.4%)   
 No/Unknown 168 (39.0%) 9599 (50.6%)   
Status (%)    773.048 < 0.001
 Alive 37 (8.6%) 13,467 (70.9%)   
 Dead 394 (91.4%) 5522 (29.1)   
 Median survival time(IQR) 5 (2–11) 29 (14–52)   
  1. Notes: LM, liver metastasis; Met, Metastasis